JP2017514907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514907A5 JP2017514907A5 JP2017510449A JP2017510449A JP2017514907A5 JP 2017514907 A5 JP2017514907 A5 JP 2017514907A5 JP 2017510449 A JP2017510449 A JP 2017510449A JP 2017510449 A JP2017510449 A JP 2017510449A JP 2017514907 A5 JP2017514907 A5 JP 2017514907A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- medulloblastoma
- agent according
- diazepin
- thieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 30
- 229940124597 therapeutic agent Drugs 0.000 claims 30
- 208000000172 Medulloblastoma Diseases 0.000 claims 20
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 12
- 239000007962 solid dispersion Substances 0.000 claims 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 101150023956 ALK gene Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 230000004069 differentiation Effects 0.000 claims 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 3
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- HMKHWYHCDUFAJR-UHFFFAOYSA-N acetamide;dihydrate Chemical compound O.O.CC(N)=O HMKHWYHCDUFAJR-UHFFFAOYSA-N 0.000 claims 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 2
- -1 compounds acetamide dihydrate Chemical class 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000009477 glass transition Effects 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 229940124291 BTK inhibitor Drugs 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims 1
- 201000004085 CLL/SLL Diseases 0.000 claims 1
- 101150030839 Klc1 gene Proteins 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 claims 1
- 101150010028 TFG gene Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims 1
- 208000014579 classic medulloblastoma Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 1
- 101150068690 eml4 gene Proteins 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 201000005833 large cell medulloblastoma Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 201000005803 melanotic medulloblastoma Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 210000003098 myoblast Anatomy 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 201000005057 nodular medulloblastoma Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987813P | 2014-05-02 | 2014-05-02 | |
| US61/987,813 | 2014-05-02 | ||
| US201461990469P | 2014-05-08 | 2014-05-08 | |
| US201461990459P | 2014-05-08 | 2014-05-08 | |
| US61/990,459 | 2014-05-08 | ||
| US61/990,469 | 2014-05-08 | ||
| PCT/US2015/028798 WO2015168555A1 (en) | 2014-05-02 | 2015-05-01 | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514907A JP2017514907A (ja) | 2017-06-08 |
| JP2017514907A5 true JP2017514907A5 (cg-RX-API-DMAC7.html) | 2018-06-14 |
Family
ID=54359380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510449A Pending JP2017514907A (ja) | 2014-05-02 | 2015-05-01 | チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170095484A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3137086A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017514907A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170002550A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106687117A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015252940A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2947593A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016014299A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016146102A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015168555A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6243003B2 (ja) | 2013-03-15 | 2017-12-06 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｂｅｔタンパク質阻害剤としての三環式複素環 |
| CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| ES2942723T3 (es) | 2014-04-23 | 2023-06-06 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET |
| KR20170037670A (ko) * | 2014-08-19 | 2017-04-04 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법 |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| WO2016176335A1 (en) * | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| RS64274B1 (sr) | 2016-06-20 | 2023-07-31 | Incyte Corp | Kristalni čvrsti oblici bet inhibitora |
| CN110996913A (zh) * | 2017-06-30 | 2020-04-10 | 欧恩科斯欧公司 | 新的贝利司他口服制剂 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2412776C (en) * | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| US8476260B2 (en) * | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| MX384074B (es) * | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| JP6265979B2 (ja) * | 2012-06-25 | 2018-01-24 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 |
| HK1211209A1 (en) * | 2012-09-28 | 2016-05-20 | Oncoethix Gmbh | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| WO2015078929A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
| EP3074019A1 (en) * | 2013-11-27 | 2016-10-05 | Oncoethix GmbH | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds |
-
2015
- 2015-05-01 MX MX2016014299A patent/MX2016014299A/es unknown
- 2015-05-01 EP EP15786309.3A patent/EP3137086A4/en not_active Withdrawn
- 2015-05-01 CA CA2947593A patent/CA2947593A1/en not_active Abandoned
- 2015-05-01 RU RU2016146102A patent/RU2016146102A/ru not_active Application Discontinuation
- 2015-05-01 US US15/308,548 patent/US20170095484A1/en not_active Abandoned
- 2015-05-01 WO PCT/US2015/028798 patent/WO2015168555A1/en not_active Ceased
- 2015-05-01 AU AU2015252940A patent/AU2015252940A1/en not_active Abandoned
- 2015-05-01 JP JP2017510449A patent/JP2017514907A/ja active Pending
- 2015-05-01 CN CN201580036829.XA patent/CN106687117A/zh active Pending
- 2015-05-01 KR KR1020167033941A patent/KR20170002550A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514907A5 (cg-RX-API-DMAC7.html) | ||
| RU2016146102A (ru) | Способ лечения резистентной неходжкинской лимфомы, медуллобластомы и/или alk+ немелкоклеточного рака легкого с применением тиенотриазолодиазепиновых соединений | |
| JP2017529332A5 (cg-RX-API-DMAC7.html) | ||
| Czodrowski et al. | Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screening | |
| Martinelli et al. | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells | |
| BR112021016132A2 (pt) | Novo derivado de pirido[3,4-d]pirimidin-8-ona tendo atividade inibitória da proteína quinase e composição farmacêutica para prevenir, aliviar ou tratar o câncer, que o compreende | |
| Daniele et al. | Dual inhibition of PDK1 and Aurora Kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells | |
| Hatcher et al. | Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation | |
| CN104619704B (zh) | 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物 | |
| JP2012136540A5 (cg-RX-API-DMAC7.html) | ||
| Yuan et al. | Identification of pyrrolo [2, 3-d] pyrimidine-based derivatives as potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia | |
| RU2017100921A (ru) | Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина | |
| JPWO2020138370A5 (cg-RX-API-DMAC7.html) | ||
| JP2021501199A5 (cg-RX-API-DMAC7.html) | ||
| JP2016525563A5 (cg-RX-API-DMAC7.html) | ||
| Schneider et al. | Rationale for MYC imaging and targeting in pancreatic cancer | |
| US20190292195A1 (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors | |
| Zhou et al. | Tellurium/bovine serum albumin nanocomposites inducing the formation of stress granules in a protein kinase R-dependent manner | |
| Xie et al. | Discovery of 2-amino-7-sulfonyl-7 H-pyrrolo [2, 3-d] pyrimidine derivatives as potent reversible FGFR inhibitors with gatekeeper mutation tolerance: design, synthesis, and biological evaluation | |
| CA2994456A1 (en) | Benzodiazepines as bromodomain inhibitors | |
| JP2011251959A5 (cg-RX-API-DMAC7.html) | ||
| US20180369241A1 (en) | Treatment of cancer with dnapk inhibitors | |
| JP2017528446A5 (cg-RX-API-DMAC7.html) | ||
| Lei et al. | Discovery of Novel, Potent, and Selective Small-Molecule Menin–Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups | |
| CN103965180B (zh) | 苯磺酰胺噁唑和噻唑激酶抑制剂 |